Matches in DBpedia 2016-04 for { <http://wikidata.dbpedia.org/resource/Q5013907> ?p ?o }
Showing triples 1 to 31 of
31
with 100 triples per page.
- Q5013907 subject Q8431759.
- Q5013907 abstract "CRLX101 is a novel approach to cancer chemotherapy that is under investigation in human trials. It is an example of a nanomedicine.The agent represents a nanoparticle conjugate that consists of a drug delivery molecule, namely a cyclodextrin-based polymer (CDP) and an anti-cancer compound (camptothecin). It was developed by Mark E. Davis, professor of Chemical Engineering at the California Institute of Technology, and associates at Insert Therapeutics, Inc., now Calando Pharmaceuticals, Inc., hence the original name "IT-101". Its novel delivery mode allows the agent, and thus the toxic anti-cancer component, to be preferentially accumulated in cancer tissue. In turn, toxic side effect are expected to be reduced. The technology was licensed by Calando and Caltech to Cerulean Pharma Inc., in June, 2009.".
- Q5013907 wikiPageExternalLink www.calandopharma.com.
- Q5013907 wikiPageExternalLink www.ceruleanrx.com.
- Q5013907 wikiPageExternalLink www.ceruleanrx.com.
- Q5013907 wikiPageExternalLink index.html.
- Q5013907 wikiPageExternalLink qa-mark-davis.
- Q5013907 wikiPageExternalLink 23.
- Q5013907 wikiPageWikiLink Q11369.
- Q5013907 wikiPageWikiLink Q11723038.
- Q5013907 wikiPageWikiLink Q12078.
- Q5013907 wikiPageWikiLink Q1275685.
- Q5013907 wikiPageWikiLink Q161562.
- Q5013907 wikiPageWikiLink Q261659.
- Q5013907 wikiPageWikiLink Q30612.
- Q5013907 wikiPageWikiLink Q3274739.
- Q5013907 wikiPageWikiLink Q407828.
- Q5013907 wikiPageWikiLink Q410083.
- Q5013907 wikiPageWikiLink Q415276.
- Q5013907 wikiPageWikiLink Q419964.
- Q5013907 wikiPageWikiLink Q5123723.
- Q5013907 wikiPageWikiLink Q6037384.
- Q5013907 wikiPageWikiLink Q620730.
- Q5013907 wikiPageWikiLink Q70702.
- Q5013907 wikiPageWikiLink Q7834538.
- Q5013907 wikiPageWikiLink Q81163.
- Q5013907 wikiPageWikiLink Q8431759.
- Q5013907 wikiPageWikiLink Q864895.
- Q5013907 wikiPageWikiLink Q974135.
- Q5013907 comment "CRLX101 is a novel approach to cancer chemotherapy that is under investigation in human trials. It is an example of a nanomedicine.The agent represents a nanoparticle conjugate that consists of a drug delivery molecule, namely a cyclodextrin-based polymer (CDP) and an anti-cancer compound (camptothecin). It was developed by Mark E.".
- Q5013907 label "CRLX101".